New hope for tough prostate cancer: experimental drug AB-3028 enters human trials

NCT ID NCT07285694

First seen Jan 04, 2026 · Last updated May 12, 2026 · Updated 21 times

Summary

This study tests an experimental drug called AB-3028 in about 190 men whose prostate cancer has spread and stopped responding to standard hormone treatments. The main goal is to find a safe dose and see if the drug can shrink tumors or slow the disease. Participants must have a specific marker (PSMA) on their cancer cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope

    RECRUITING

    Duarte, California, 91010, United States

  • Perlmutter Cancer Center - NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

  • USC Norris Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90033, United States

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

  • University of Iowa and Holden Comprehensive Cancer Center

    RECRUITING

    Iowa City, Iowa, 52242, United States

  • University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

Conditions

Explore the condition pages connected to this study.